Gene therapy breakthrough? first human test of TN-201 for heart muscle disease begins
Disease control
Recruiting now
This study tests a new gene therapy called TN-201 in 30 adults with hypertrophic cardiomyopathy caused by a specific genetic mutation (MYBPC3). The therapy is given as a one-time IV infusion and aims to correct the underlying genetic defect. The main goals are to check safety and…
Phase: PHASE1, PHASE2 • Sponsor: Tenaya Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC